Nexttrip, Inc. annual report, FY2014

Business context and reporting period

Filing identity mismatch: The request identifies Nexttrip, Inc., but the supplied Form 10-K is for Sigma Labs, Inc. This summary covers Sigma Labs’ fiscal year ended December 31, 2014, compared with fiscal 2013; it is not a standalone fourth-quarter report. Sigma Labs develops in-process quality assurance technology for additive manufacturing (3D printing), provides engineering consulting, and began building a metal 3D-printing contract manufacturing business. Its PrintRite3D products were in early commercialization, and the company reported no technology product sales.

Key financial metrics

Revenue fell approximately 49%. General and administrative expense was $1,239,394, payroll expense $404,054, noncash stock compensation $582,550, and research and development expense $219,132. A $1,283,333 warrant expense—associated with extending an investor warrant—was a major noncash charge. The company reported no interest expense or credit facility; the balance sheet lists no debt. Cash flow from financing was $3,697,791, principally reflecting equity proceeds. Investing cash outflow was $839,610, including equipment purchases. The EOS M290 metal printer was acquired for approximately $724,000, with $241,333 paid in early 2015.

Material changes versus prior period

• Revenue declined because a Sumner Associates contract was not renewed and work on several customer and research contracts started later than expected. Sumner Associates was dissolved during 2014.
• Net loss increased by about $2.38 million as revenue decreased and operating costs rose; the warrant charge and increased payroll, stock compensation, R&D, and administrative costs were significant factors.
• Gross margin improved, while operating cash use increased. Cash and working capital rose largely because of equity financing, including 50 million shares sold in 2014 for $4.0 million gross proceeds.
• Property and equipment increased substantially following the metal printer purchase; the printer was installed and integrated with PrintRite3D in early 2015.

Outlook, risks, and unusual items

Management expected to pursue commercialization of PrintRite3D in the remainder of 2015 and 2016, expand sales and marketing, and grow contract manufacturing. As of March 31, 2015, three active consulting contracts were expected to generate up to approximately $989,000 in 2015, contingent on milestones. A Honeywell/DARPA Phase II project had an approximately $500,000 total award value to Sigma, with about $59,000 generated in 2014; a NIST-related contract was expected to generate about $150,000 in total, of which $112,478 was generated in 2014. These are expectations, not guaranteed revenue. Management said available funds and expected contract revenue should cover operations during 2015; elsewhere, the filing says cash and existing-contract revenue were expected to fund operations for at least 18 months, subject to assumptions and uncertainty.

• Material risks include continued losses, uncertain product commercialization, reliance on consulting contracts and equity financing, customer concentration, fixed-price contract cost overruns, and dependence on a small workforce and key personnel.
• Four customers accounted for 96% of 2014 revenue in aggregate; individual customer shares were 30%, 27%, 21%, and 18%. Customer identities are anonymized in the financial statement note.
• As of March 31, 2015, the company said it could not use its effective Form S-3 offering registration because its nonaffiliate market value was below the $75 million eligibility threshold. Additional financing could dilute shareholders; management gave no assurance it could obtain funding.
• The filing reports no current legal proceedings. It identifies government-contract compliance, intellectual-property protection, competition, and limited financial controls/staffing as risks. Management concluded disclosure controls and internal control over financial reporting were effective at a reasonable assurance level; there was no auditor attestation of internal controls.
• The 2014 statements were audited, and the auditor issued an unqualified opinion on the financial statements. The auditor did not opine on internal-control effectiveness.

Important facts for investors to verify

1. Confirm the issuer and period: the supplied document is Sigma Labs’ FY 2014 10-K, not a Nexttrip filing or a standalone Q4 report.
2. Track whether 2015 contract milestones were met and whether expected revenues were realized, especially the Honeywell/DARPA, NIST-related, and other consulting work.
3. Verify PrintRite3D commercialization, customer adoption, recurring product or licensing revenue, and contract manufacturing utilization; the filing reported no technology product sales.
4. Assess cash burn and funding needs against the reported cash balance, the printer’s remaining payment, and management’s conditional liquidity outlook.
5. Review dilution and warrant overhang: 612,741,061 common shares were outstanding at year-end 2014, with 18,796,296 warrants outstanding; the filing reported 623,344,835 shares outstanding at March 31, 2015.
6. Reconcile the small one-dollar difference in the filing’s presentation of 2014 net loss ($3,116,080 in the statements of operations and cash flows versus $3,116,081 in the statement of stockholders’ equity).